Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple drugs (Selonsertib, Firsocostat, Cilofexor, and combinations) for bridging fibrosis or compensated cirrhosis due to nonalcohol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cilofexor (cilofexor)
• Firsocostat (firsocostat)
• Selonsertib (selonsertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-12-03